Study of Optimal Replacement of Thyroxine in the Elderly (SORTED) - results from the feasibility randomised controlled trial

Salman Razvi, Lorna Ingoe, Vicky Ryan, Simon H S Pearce, Scott Wilkes, Salman Razvi, Lorna Ingoe, Vicky Ryan, Simon H S Pearce, Scott Wilkes

Abstract

Background: Hypothyroidism is a common condition, particularly in the older population. Thyroid hormone requirements change with age and serum TSH levels also alter, especially in older patients. However, in practice laboratory reference ranges for thyroid function are not age-specific and treatment in older patients aims to achieve a similar target thyroid function level as younger age groups.

Methods: A dual centre, single blind, randomised controlled trial was conducted to determine the feasibility of a future definitive RCT in hypothyroid individuals aged 80 years or older who were treated with levothyroxine. Potential participants were identified from 17 research-active GP practices (n = 377), by opportunistic invitations (n = 9) or in response to publicity (n = 4). Participants were randomly allocated to either usual (0.4-4.0 mU/L) or a higher (4.1-8.0 mU/L) target serum TSH range. Information on participants' willingness to enter the trial, acceptability of study design, length of time to complete recruitment and dose titration strategy was collected.

Results: Fifteen percent (57/390) of potentially eligible hypothyroid individuals consented to participate in this trial and 48 were randomised to trial medication for 24 weeks, giving a recruitment rate of 12 %. Recruitment averaged 5.5 participants per month over approximately 9 months. Eight participants withdrew (3/24 and 5/24 in the usual and higher TSH arms, respectively) with the commonest reason cited (5 patients) being tiredness. Interestingly, 3/5 participants withdrew from the site that required a visit to a Research Facility whereas only 5/43 participants withdrew from the site that offered home visits. In the higher TSH arm, of those participants who completed the study, approximately half of participants (10/19) reached target TSH.

Conclusions: It is feasible to perform a randomised controlled trial of thyroid hormones in hypothyroid patients aged 80 or older. A definitive trial would require collaboration with a large number of General Practices and the provision of home visits to achieve recruitment to time and target. Power calculations should take into account that approximately 12 % of those approached will be randomised and 1 in 6 participants are likely to withdraw from the study. Finally, several dose adjustments may be required to achieve target serum TSH levels in this age group.

Trial registration: ISRCTN Number: 16043724 Registered 22 June 2012 Clinicaltrial.gov Number: NCT01647750 EudraCT Number: 2011-004425-27.

Keywords: Feasibility; Hypothyroidism; Older age.

Figures

Fig. 1
Fig. 1
Recruitment summary
Fig. 2
Fig. 2
Plot of cumulative number of patients randomised, target versus actual

References

    1. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526–34. doi: 10.1001/archinte.160.4.526.
    1. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) J Clin Endocrinol Metab. 2002;87(2):489. doi: 10.1210/jcem.87.2.8182.
    1. Leese GP, Flynn RV, Jung RT, Macdonald TM, Murphy MJ, Morris AD. Increasing prevalence and incidence of thyroid disease in Tayside, Scotland: the Thyroid Epidemiology Audit and Research Study (TEARS) Clin Endocrinol (Oxf) 2008;68(2):311–6.
    1. Flynn RW, MacDonald TM, Morris AD, Jung RT, Leese GP. The thyroid epidemiology, audit, and research study: thyroid dysfunction in the general population. J Clin Endocrinol Metab. 2004;89(8):3879–84. doi: 10.1210/jc.2003-032089.
    1. Mitchell AL, Hickey B, Hickey JL, Pearce SH. Trends in thyroid hormone prescribing and consumption in the UK. BMC Public Health. 2009;9:132. doi: 10.1186/1471-2458-9-132.
    1. Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab. 2007;92(12):4575–82. doi: 10.1210/jc.2007-1499.
    1. Vadiveloo T, Donnan PT, Murphy MJ, Leese GP. Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: the Thyroid Epidemiology, Audit, and Research Study (TEARS) J Clin Endocrinol Metab. 2013;98(3):1147–53. doi: 10.1210/jc.2012-3191.
    1. Ehrenkranz J, Bach PR, Snow GL, Schneider A, Lee JL, Ilstrup S, Bennett ST, Benvenga S. Circadian and circannual rhythms in thyroid hormones: determining the TSH and free T4 reference intervals based upon time of day, age, and sex. Thyroid. 2015;25(8):954–61. doi: 10.1089/thy.2014.0589.
    1. Bremner AP, Feddema P, Leedman PJ, Brown SJ, Beilby JP, Lim EM, Wilson SG, O’Leary PC, Walsh JP. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab. 2012;97(5):1554–62. doi: 10.1210/jc.2011-3020.
    1. Atzmon G, Barzilai N, Hollowell JG, Surks MI, Gabriely I. Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab. 2009;94(4):1251–4. doi: 10.1210/jc.2008-2325.
    1. Virgini VS, Wijsman LW, Rodondi N, Bauer DC, Kearney PM, Gussekloo J, den Elzen WP, Jukema JW, Westendorp RG, Ford I, Stott DJ, Mooijaart SP, PROSPER Study Group Subclinical thyroid dysfunction and functional capacity among elderly. Thyroid. 2014;24(2):208–14. doi: 10.1089/thy.2013.0071.
    1. Simonsick EM, Newman AB, Ferrucci L, Satterfield S, Harris TB, Rodondi N, Bauer DC, Health ABC Study Subclinical hypothyroidism and functional mobility in older adults. Arch Intern Med. 2009;169(21):2011–7. doi: 10.1001/archinternmed.2009.392.
    1. Blum MR, Wijsman LW, Virgini VS, Bauer DC, den Elzen WP, Jukema JW, Buckley BM, de Craen AJ, Kearney PM, Stott DJ, Gussekloo J, Westendorp RG, Mooijaart SP, Rodondi N, PROSPER study group Subclinical thyroid dysfunction and depressive symptoms among the elderly: a prospective cohort study. Neuroendocrinology. 2016;103(3-4):291–9. doi: 10.1159/000437387.
    1. Hyland KA, Arnold AM, Lee JS, Cappola AR. Persistent subclinical hypothyroidism and cardiovascular risk in the elderly: the cardiovascular health study. J Clin Endocrinol Metab. 2013;98(2):533–40. doi: 10.1210/jc.2012-2180.
    1. Waring AC, Arnold AM, Newman AB, Bùzková P, Hirsch C, Cappola AR. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. J Clin Endocrinol Metab. 2012;97(11):3944–50. doi: 10.1210/jc.2012-2481.
    1. Pearce SH, Razvi S, Yadegarfar ME, Martin-Ruiz C, Kingston A, Collerton J, Visser TJ, Kirkwood TB, Jagger C. Serum thyroid function, mortality and disability in advanced old age: The Newcastle 85+ study. J Clin Endocrinol Metab. 2016;23:jc20161935. doi: 10.1210/jc.2016-1935.
    1. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292(21):2591–9. doi: 10.1001/jama.292.21.2591.
    1. Taylor PN, Iqbal A, Minassian C, Sayers A, Draman MS, Greenwood R, Hamilton W, Okosieme O, Panicker V, Thomas SL, Dayan C. Falling threshold for treatment of borderline elevated thyrotropin levels – balancing benefits and risks. Evidence from a large community-based study. JAMA Intern Med. 2014;174(1):32–9. doi: 10.1001/jamainternmed.2013.11312.
    1. Wilkes S, Pearce S, Ryan V, Rapley T, Ingoe L, Razvi S. Study of Optimal Replacement of Thyroxine in the ElDerly (SORTED): protocol for a mixed methods feasibility study to assess the clinical utility of lower dose thyroxine in elderly hypothyroid patients: study protocol for a randomized controlled trial. Trials. 2013;14:83. doi: 10.1186/1745-6215-14-83.
    1. Lancaster GA, Dodd S, Williamson PR, et al. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004;10:307–12. doi: 10.1111/j..2002.384.doc.x.
    1. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010;10:1. doi: 10.1186/1471-2288-10-1.
    1. UK National Statistics. . Accessed 17 June 2016.
    1. 2014 National Population Projections. 2014; . Accessed 17 June 2016.
    1. Parle JV, Franklyn JA, Cross KW, Jones SR, Sheppard MC. Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br J Gen Pract. 1993;43(368):107–9.
    1. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95(1):186–93. doi: 10.1210/jc.2009-1625.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться